An oft-cited advantage of these agents, compared with VKAs, is that like antiplatelet drugs, no routine monitoring is required (1,2). However, there are numerous situations in which the precise anticoagulant status of a particular patient is needed, such as before emergency surgery or other invasive procedure; in the face of evident or suspected hemorrhage; when there is suspicion of overdose; in acute thrombosis; in renal, liver, or heart failure; when proof of compliance is required; in potential drugdrug interactions; and in cases of trauma, acute medical disease, and malignancy (3). In these cases, some of which may be life threatening, the laboratory needs to be able to offer some support.
In this respect, the problem is that the "standard" 
